The role of thrombolytic therapy in the management of paradoxical embolism

Vascular

Volumn 6, Issue 3, 1998, Pages 302-306

  D'audiffret, A ^a   Shenoy, S S ^b   Ricotta, J J ^a   Dryjski, M ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b MILLARD FILLMORE HOSPITAL   (United States)

Author keywords

paradoxical embolism; pulmonary embolism; thrombolytic therapy

Indexed keywords

UROKINASE;

AGED; ARTICLE; CASE REPORT; FEMALE; FIBRINOLYTIC THERAPY; HEART ATRIUM SEPTUM DEFECT; HUMAN; LUNG EMBOLISM; PARADOXICAL EMBOLISM; PRIORITY JOURNAL; TREATMENT INDICATION;

AGED; ANGIOGRAPHY; EMBOLISM, PARADOXICAL; FEMALE; HEART SEPTAL DEFECTS, ATRIAL; HUMANS; ISCHEMIA; LEG; PLASMINOGEN ACTIVATORS; PULMONARY EMBOLISM; THROMBOLYTIC THERAPY; THROMBOSIS; URINARY PLASMINOGEN ACTIVATOR; VENA CAVA FILTERS;

EID: 0032103674     PISSN: 17085381     EISSN: None     Source Type: Journal    
DOI: 10.1177/096721099800600314     Document Type: Article

References (25)

1. Cohnheim J., Thrombose und embolie. In Vorlesungen über Allgemeine Pathologie, Vol 1. Hischwaldd, Berlin, 1877. p. 134.
2. Biller J., Johnson M.R., Adams H.P. Jr., et al, Further observations on cerebral or retinal ischemia in patients with right-left intracardiac shunts. Archives of Neurology, 1987, 44, 740–743.
3. Thompson T., Evans W., Pradoxical embolism. Quarterly Journal of Medicine, 1930, 23, 135–150.
4. Hagen P.T., Scholz D.G., Edwards W.D., Incidence and size of patent foramen ovale during the first 10 decades of life: An autopsy study of 965 normal hearts. Mayo Clinic Proceedings, 1984, 59, 17–20.
5. Anderson F.A. Jr., Wheeler H.B., Goldberg R.J., A population based perspective of the hospital incidence and case-fatality rates of venous thrombosis and pulmonary embolism: The Worcester DVT study. Archive of Internal Medicine, 1991, 151, 933–938.
6. Loscalzo J., Paradoxical embolism: Clinical presentation, diagnostic strategies, and therapeutic options. American Heart Journal, 1986, 112, 141–145.
7. Goldhaber S.Z., Haire W.D., Feldstein M.L., Alteplase versus heparin in acute pulmonary embolism: Randomized trial assessing right ventricular function and pulmonary reperfusion. Lancet, 1993, 341, 507–511.
8. Stöllberger C., Slany J., Schuster I., et al, The prevalence of deep venous thrombosis in patients with suspected paradoxical embolism. Annals of Internal Medicine, 1993, 119(6), 461–465.
9. Goldhaber S.Z., Contemporary pulmonary embolism thrombolysis. Chest, 1995, 107, 45S-51S.
10. A collaborative study by the PIOPED Investigators. Tissue plasminogen activator for the treatment of acute pulmonary embolism. Chest, 1990, 97, 528–533.
11. Dalla-Volta S., Palla A., Santdicancho A., et al, PAIMS 2: Alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism plasminogen activator. Italian multicenter study 2. Journal American College of Cardiology, 1992, 20, 520–526.
12. Levine M., Hirsh J., Weitz J., et al, A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest, 1990, 98, 1473–1479.
13. The UKEP Study Research Group. The UKEP study: Multicenter clinical trial on two local regimens of Urokinase in massive pulmonary embolism. European Heart Journal, 1987, 8, 2–10.
14. The Urokinase Pulmonary Embolism Trial. A national cooperative study. Circulation, 1973, 47, 1–108.
15. Urokinase Pulmonary Embolism Trial Study Group: Urokinase pulmonary embolism trial, phase I results. Journal of the American Medical Association, 1970, 214, 2163–2172.
16. Gonzalez-Juanatey J.R., Valdés L., Amaro A., et al, Treatment of massive pulmonary thromboembolism with low intrapulmonary dosages of urokinase. Chest, 1992, 102(2), 341–346.
17. Leeper K.V., Popovich J., Lesser B.A., et al, Treatment of massive acute pulmonary embolism: The use of low doses of intrapulmonary streptokinase combined with full doses of systemic heparin. Chest, 1988, 93(2), 234–240.
18. Molina E.J., Hunter D.W., Yedlicka J.W., Cerra F.B., Thrombolytic therapy for postoperative pulmonary embolism. American Journal of Surgery, 1992, 163, 375–380.
19. Verstraete M., Miller G.A.H., Bounameaux H., et al, Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. Circulation, 1988, 77(2), 353–360.
20. Tapson V.F., Gurbel P.A., Witty L.A., et al, Pharmacomcchanical thrombolysis of experimental pulmonary emboli: Rapid low dose intraembolic therapy. Chest, 1994, 106(5), 1558–1562.
21. Schwarz F., Stehr H., Zimmermann R., et al, Sustained improvement of pulmonary hemodynamics in patients at rest and during exercise after thrombolytic treatment of massive pulmonary embolism. Circulation, 1985, 71(1), 117–123.
22. Thery C., Asseman P., Amrouni N., et al, Use of a new removable vena cava filter in order to prevent pulmonary embolism in patients submitted to thrombolysis. European Heart Journal, 1990, 11, 334–341.
23. Dalman R., Kohler T.R., Cerebrovascular accident after Greenfield filter placement for paradoxical embolism. Journal of Vascular Surgery, 1989, 9, 452–454.
24. Katz S., Andros G., Kohl R., et al, Arterial emboli of venous origin. Surgery, 1992, 174, 17–21.
25. Petitpretzor P., Simmoneau G., Cerrince J., et al, Effect of a single bolus of Urokinase in patients with life threatening pulmonary emboli: A descriptive trial. Circulation, 1984, 10, 861–866.